• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Alzeca Biosciences raises $11m for Alzheimer’s diagnostic imaging agent

August 17, 2017 By Sarah Faulkner

Alzeca BiosciencesAlzeca Biosciences said today that it raised $11 million in a Series A round to fund the development of its MRI imaging agent designed for the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders.

The company touts its ADx nanoparticle as the first MRI contrast agent to target amyloid – a brain protein linked to Alzheimer’s disease. Alzeca said that its newly-acquired funds will help bring its imaging compound through Phase I clinical trials.

“We are very pleased to complete this significant round of financing with experienced private investors who have a firm commitment to advancing these urgently needed healthcare innovations in Alzheimer’s disease and other types of dementia,” Alzeca CEO Carlo Medici said in prepared remarks.

With conventional methods, it’s difficult to accurately diagnose patients with Alzheimer’s disease. Although recent research has shown that PET brain imaging of amyloid plaque buildup could boost dementia diagnosis in some patients, Alzeca pointed out that PET imaging is costly and not widely-available to healthcare providers.

MRI technology is more broadly available than PET imaging and doesn’t expose patients to radiation. Being able to detect Alzheimer’s disease before symptoms appear could change the way that the debilitating neurological condition is treated, the Houston-based company said.

In connection with the Series A round, Chemwerth president & CEO Peter Werth, Jr., and Nevakar founder & CEO Navneet Puri joined Alzeca’s board of directors.

“The ability to diagnose neurodegenerative diseases such as Alzheimer’s years before serious cognitive impairment manifests, so as to potentially intervene therapeutically at an early stage in the disease process, is a significant healthcare challenge,” Werth said. “We are excited to partner with Alzeca because its promising MRI brain imaging agents offer great potential not only to advance the early diagnosis of such conditions but also to aid in monitoring patient response to treatment both during drug development and in the clinic.”

“Alzeca is addressing a critical healthcare need and has assembled a highly experienced management team composed of world-renowned experts in diagnostic imaging, clinical neurosciences and commercial pharmaceutical and biomedical development,” Puri added. “Bringing novel diagnostic approaches and more accurate biomarkers to address the challenges of Alzheimer’s disease and other neurodegenerative diseases is a worthy cause and will benefit millions of patients, caregivers and healthcare providers. I am very happy to support them and invest in this endeavor.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diagnostics, Featured, Funding Roundup, Imaging, Nanoparticles, Neurological Tagged With: alzecabiosciences

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS